{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T01:19:58Z","timestamp":1785374398242,"version":"3.55.0"},"reference-count":161,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,7,1]],"date-time":"2024-07-01T00:00:00Z","timestamp":1719792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.es","elsevier.es","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"published-print":{"date-parts":[[2024,7]]},"DOI":"10.1016\/j.arteri.2024.03.002","type":"journal-article","created":{"date-parts":[[2024,4,9]],"date-time":"2024-04-09T13:11:45Z","timestamp":1712668305000},"page":"243-266","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Consenso sobre lipoprote\u00edna (a) de la Sociedad Espa\u00f1ola de Arteriosclerosis. Revisi\u00f3n bibliogr\u00e1fica y recomendaciones para la pr\u00e1ctica cl\u00ednica"],"prefix":"10.1016","volume":"36","author":[{"given":"Javier","family":"Delgado-Lista","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Mostaza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teresa","family":"Arrobas-Velilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Blanco-Vaca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Masana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pedro-Botet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Perez-Martinez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Civeira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose I.","family":"Cuende-Melero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose J.","family":"Gomez-Barrado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Lahoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Pint\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel","family":"Suarez-Tembra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Lopez-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Guijarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.arteri.2024.03.002_bib0810","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1111\/j.1699-0463.1963.tb01808.x","article-title":"A New Serum Type System in Man--The Lp System","volume":"59","author":"Berg","year":"1963","journal-title":"Acta Pathol Microbiol Scand"},{"key":"10.1016\/j.arteri.2024.03.002_bib0815","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1111\/j.1399-0004.1974.tb00657.x","article-title":"Lp(a) lipoprotein and pre-beta1-lipoprotein in patients with coronary heart disease","volume":"6","author":"Berg","year":"1974","journal-title":"Clin Genet"},{"key":"10.1016\/j.arteri.2024.03.002_bib0820","first-page":"349","article-title":"Genetics of the Lp System","volume":"13","author":"Berg","year":"1963","journal-title":"Acta Genet Stat Med."},{"key":"10.1016\/j.arteri.2024.03.002_bib0825","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1161\/ATV.0000000000000147","article-title":"Lipoprotein(a): A Genetically Determined, Causal, and Prevalent Risk Factor for Atherosclerotic Cardiovascular Disease: A Scientific Statement From the American Heart Association","volume":"42","author":"Reyes-Soffer","year":"2022","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0830","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0009-3084(94)90122-8","article-title":"Identification and quantification of apolipoproteins in addition to apo[a] and apo B-100 in human lipoprotein[a]","volume":"67\u201368","author":"Blanco-Vaca","year":"1994","journal-title":"Chem Phys Lipids"},{"key":"10.1016\/j.arteri.2024.03.002_bib0835","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/330132a0","article-title":"cDNA sequence of human apolipoprotein(a) is homologous to plasminogen","volume":"330","author":"McLean","year":"1987","journal-title":"Nature"},{"key":"10.1016\/j.arteri.2024.03.002_bib0840","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1161\/01.ATV.16.6.713","article-title":"Apolipoprotein(a) kringle IV repeat number predicts risk for coronary heart disease","volume":"16","author":"Kraft","year":"1996","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0845","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/00041433-200404000-00009","article-title":"Structure-function relationships in apolipoprotein(a): Insights into lipoprotein(a) assembly and pathogenicity","volume":"15","author":"Koschinsky","year":"2004","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0850","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1172\/JCI119055","article-title":"Kringle-containing fragments of apolipoprotein(a) circulate in human plasma and are excreted into the urine","volume":"98","author":"Mooser","year":"1996","journal-title":"J Clin Invest"},{"key":"10.1016\/j.arteri.2024.03.002_bib0855","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/ejhg.2008.114","article-title":"Genome-wide linkage analysis for identifying quantitative trait loci involved in the regulation of lipoprotein a (Lpa) levels","volume":"16","author":"Lopez","year":"2008","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.arteri.2024.03.002_bib0860","doi-asserted-by":"crossref","first-page":"3925","DOI":"10.1093\/eurheartj\/ehac361","article-title":"Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society consensus statement","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.03.002_bib0865","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1194\/jlr.M076232","article-title":"A genome-wide association meta-analysis on lipoprotein (a) concentrations adjusted for apolipoprotein (a) isoforms","volume":"58","author":"Mack","year":"2017","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.03.002_bib0870","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.atherosclerosis.2022.04.003","article-title":"Lipoprotein(a) beyond the kringle IV repeat polymorphism: The complexity of genetic variation in the LPA gene","volume":"349","author":"Coassin","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib0875","doi-asserted-by":"crossref","first-page":"e3594","DOI":"10.1210\/clinem\/dgac412","article-title":"Triglyceride Metabolism Modifies Lipoprotein(a) Plasma Concentration","volume":"107","author":"Ramos-Caceres","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.arteri.2024.03.002_bib0880","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1194\/jlr.R083626","article-title":"The role of lipoprotein (a) in chronic kidney disease","volume":"59","author":"Hopewell","year":"2018","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.03.002_bib0885","doi-asserted-by":"crossref","first-page":"480784","DOI":"10.1155\/2012\/480784","article-title":"A Systematic Literature Review of the Association of Lipoprotein(a) and Autoimmune Diseases and Atherosclerosis","volume":"2012","author":"Missala","year":"2012","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0890","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1161\/01.ATV.20.4.1137","article-title":"Major reduction in plasma Lp(a) levels during sepsis and burns","volume":"20","author":"Mooser","year":"2000","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0895","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/MOL.0000000000000681","article-title":"Lipoprotein(a): Is it more, less or equal to LDL as a causal factor for cardiovascular disease and mortality?","volume":"31","author":"Langsted","year":"2020","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0900","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/S0021-9150(99)00064-7","article-title":"Atherogenecity of lipoprotein(a) and oxidized low density lipoprotein: Insight from in vivo studies of arterial wall influx, degradation and efflux","volume":"143","author":"Nielsen","year":"1999","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib0905","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2021.10.044","article-title":"Association of Lipoprotein(a) With Atherosclerotic Plaque Progression","volume":"79","author":"Kaiser","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0910","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1161\/CIRCULATIONAHA.116.020838","article-title":"Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans","volume":"134","author":"van der Valk","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.03.002_bib0915","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1194\/jlr.P094763","article-title":"Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis","volume":"60","author":"Boffa","year":"2019","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.03.002_bib0920","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1016\/j.jacc.2012.01.078","article-title":"Apolipoprotein(a) genetic sequence variants associated with systemic atherosclerosis and coronary atherosclerotic burden but not with venous thromboembolism","volume":"60","author":"Helgadottir","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0925","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.hlc.2022.11.015","article-title":"Australian Atherosclerosis Society Position Statement on Lipoprotein(a): Clinical and Implementation Recommendations","volume":"32","author":"Ward","year":"2023","journal-title":"Heart Lung Circ"},{"key":"10.1016\/j.arteri.2024.03.002_bib0930","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1093\/clinchem\/41.2.246","article-title":"Effect of the number of apolipoprotein(a) kringle 4 domains on immunochemical measurements of lipoprotein(a)","volume":"41","author":"Marcovina","year":"1995","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib0935","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.cca.2020.02.030","article-title":"Lipoprotein(a) particle number assay without error from apolipoprotein(a) size isoforms","volume":"505","author":"Contois","year":"2020","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.arteri.2024.03.002_bib0940","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1016\/S0022-2275(20)31535-2","article-title":"Isolation, quantitation, and characterization of a stable complex formed by Lp[a] binding to triglyceride-rich lipoproteins","volume":"42","author":"Gaubatz","year":"2001","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.03.002_bib0945","first-page":"8","article-title":"Molecular Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?","author":"Ward","year":"2019","journal-title":"J Clin Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib0950","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1016\/j.jacl.2018.07.003","article-title":"Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size","volume":"12","author":"Tsimikas","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib0955","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1373\/clinchem.2003.023689","article-title":"Report of the National Heart, Lung, and Blood Institute Workshop on Lipoprotein(a) and Cardiovascular Disease: Recent advances and future directions","volume":"49","author":"Marcovina","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib0960","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.atherosclerosis.2019.08.015","article-title":"Comparison of lipoprotein (a) serum concentrations measured by six commercially available immunoassays","volume":"289","author":"Scharnagl","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib0965","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1194\/jlr.R061648","article-title":"Lipoprotein (a) measurements for clinical application","volume":"57","author":"Marcovina","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.03.002_bib0970","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1046\/j.1440-6047.2000.00190.x","article-title":"Plasma lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in an Aboriginal population from Western Australia","volume":"9","author":"Xiong","year":"2000","journal-title":"Asia Pac J Clin Nutr"},{"key":"10.1016\/j.arteri.2024.03.002_bib0975","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1093\/clinchem\/hvaa239","volume":"67","author":"Cobbaert","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib0980","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/clinchem\/hvac203","article-title":"Commutability Assessment of Candidate Reference Materials for Lipoprotein(a) by Comparison of a MS-based Candidate Reference Measurement Procedure with Immunoassays","volume":"69","author":"Dikaios","year":"2023","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib0985","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/clinchem\/hvac204","article-title":"Development of an LC-MRM-MS-Based Candidate Reference Measurement Procedure for Standardization of Serum Apolipoprotein (a) Tests","volume":"69","author":"Ruhaak","year":"2023","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib0990","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.atherosclerosis.2022.04.008","article-title":"Lipoprotein(a) measurement issues: Are we making a mountain out of a molehill?","volume":"349","author":"Kronenberg","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib0995","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1097\/MOL.0000000000000855","article-title":"Consensus and guidelines on lipoprotein(a) - seeing the forest through the trees","volume":"33","author":"Kronenberg","year":"2022","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1000","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1093\/clinchem\/hvaa247","article-title":"Lipoprotein(a) and Cardiovascular Disease","volume":"67","author":"Kamstrup","year":"2021","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib1005","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1016\/j.jacc.2012.12.023","article-title":"Extreme lipoprotein(a) levels and improved cardiovascular risk prediction","volume":"61","author":"Kamstrup","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1010","doi-asserted-by":"crossref","first-page":"2760","DOI":"10.1093\/eurheartj\/ehy902","article-title":"High lipoprotein(a) and high risk of mortality","volume":"40","author":"Langsted","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.03.002_bib1015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1001\/jama.2009.1063","article-title":"Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality","volume":"302","author":"Emerging Risk Factors","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2024.03.002_bib1020","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1161\/CIRCULATIONAHA.111.045120","article-title":"Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: The Atherosclerosis Risk in Communities (ARIC) Study","volume":"125","author":"Virani","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.03.002_bib1025","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1161\/ATVBAHA.120.315291","article-title":"Lp(a) (Lipoprotein[a]) Concentrations and Incident Atherosclerotic Cardiovascular Disease: New Insights From a Large National Biobank","volume":"41","author":"Patel","year":"2021","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1030","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/S2213-8587(16)30042-0","article-title":"High lipoprotein(a) as a possible cause of clinical familial hypercholesterolaemia: A prospective cohort study","volume":"4","author":"Langsted","year":"2016","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1035","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1016\/j.jacl.2018.08.012","article-title":"Lipoprotein(a) and secondary prevention of atherothrombotic events: A critical appraisal","volume":"12","author":"Boffa","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1040","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1161\/ATVBAHA.119.312951","article-title":"Lipoprotein(a)-Lowering by 50mg\/dl (105 nmol\/l) May Be Needed to Reduce Cardiovascular Disease 20% in Secondary Prevention: A Population-Based Study","volume":"40","author":"Madsen","year":"2020","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.jacc.2013.09.042","article-title":"Lipoprotein(a) for risk assessment in patients with established coronary artery disease","volume":"63","author":"O\u2019Donoghue","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1050","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa0902604","article-title":"Genetic variants associated with Lp(a) lipoprotein level and coronary disease","volume":"361","author":"Clarke","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1055","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1177\/2047487312451238","article-title":"Prevalence of calcific aortic valve disease in the elderly and associated risk factors: A population-based study in a Mediterranean area","volume":"20","author":"Ferreira-Gonzalez","year":"2013","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1060","doi-asserted-by":"crossref","first-page":"2389","DOI":"10.1056\/NEJMoa043876","article-title":"A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis","volume":"352","author":"Cowell","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1065","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1056\/NEJMoa0804602","article-title":"Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis","volume":"359","author":"Rossebo","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1070","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1075","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1080","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.pcad.2020.06.002","article-title":"Lipoprotein(a) and calcific aortic valve stenosis: A systematic review","volume":"63","author":"Guddeti","year":"2020","journal-title":"Prog Cardiovasc Dis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1085","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1136\/heartjnl-2021-319044","article-title":"Lipoprotein(a) is robustly associated with aortic valve calcium","volume":"107","author":"Kaiser","year":"2021","journal-title":"Heart"},{"key":"10.1016\/j.arteri.2024.03.002_bib1090","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jamacardio.2020.0728","article-title":"An Exploratory Analysis of Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibition and Aortic Stenosis in the FOURIER Trial","volume":"5","author":"Bergmark","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1095","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.jchf.2015.08.006","article-title":"Elevated Lipoprotein(a) Levels, LPA Risk Genotypes, and Increased Risk of Heart Failure in the General Population","volume":"4","author":"Kamstrup","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.arteri.2024.03.002_bib1100","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1016\/j.jacc.2022.02.018","article-title":"Elevated Lipoprotein(a) and Risk of Atrial Fibrillation: An Observational and Mendelian Randomization Study","volume":"79","author":"Mohammadi-Shemirani","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1105","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jacc.2019.03.524","article-title":"Elevated Lipoprotein(a) and Risk of Ischemic Stroke","volume":"74","author":"Langsted","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1110","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.atherosclerosis.2015.08.021","article-title":"Lipoprotein (a) as a risk factor for ischemic stroke: A meta-analysis","volume":"242","author":"Nave","year":"2015","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1115","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1161\/STROKEAHA.116.014436","article-title":"Lipoprotein(a) Levels and Recurrent Vascular Events After First Ischemic Stroke","volume":"48","author":"Lange","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2024.03.002_bib1120","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1161\/STROKEAHA.121.034924","article-title":"Effect of Lipoprotein(a) on Stroke Recurrence Attenuates at Low LDL-C (Low-Density Lipoprotein) and Inflammation Levels","volume":"53","author":"Xu","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2024.03.002_bib1125","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/eurheartj\/ehl441","article-title":"Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study","volume":"28","author":"Tzoulaki","year":"2007","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.03.002_bib1130","doi-asserted-by":"crossref","first-page":"e005967","DOI":"10.1161\/JAHA.117.005967","article-title":"Twenty-Year Predictors of Peripheral Arterial Disease Compared With Coronary Heart Disease in the Scottish Heart Health Extended Cohort (SHHEC)","volume":"6","author":"Tunstall-Pedoe","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.arteri.2024.03.002_bib1135","doi-asserted-by":"crossref","first-page":"3058","DOI":"10.1161\/ATVBAHA.112.255521","article-title":"Lipoprotein(a) and risk of coronary, cerebrovascular, and peripheral artery disease: The EPIC-Norfolk prospective population study","volume":"32","author":"Gurdasani","year":"2012","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1140","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.atherosclerosis.2018.07.001","article-title":"Lipoprotein (a) levels and outcomes in stable outpatients with symptomatic artery disease","volume":"276","author":"Sanchez Munoz-Torrero","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1145","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1177\/1358863X221091320","article-title":"Elevated lipoprotein (a) levels and risk of peripheral artery disease outcomes: A systematic review","volume":"27","author":"Masson","year":"2022","journal-title":"Vasc Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1150","first-page":"11","article-title":"Lipoprotein(a), Immunity, and Inflammation in Polyvascular Atherosclerotic Disease","volume":"8","author":"Tmoyan","year":"2021","journal-title":"J Cardiovasc Dev Dis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1155","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/S2213-8587(18)30290-0","article-title":"Polyvascular disease, type 2 diabetes, and long-term vascular risk: A secondary analysis of the IMPROVE-IT trial","volume":"6","author":"Bonaca","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1160","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s00380-022-02163-3","article-title":"Predictive value of lipoprotein(a) for assessing the prevalence and severity of lower-extremity peripheral artery disease among patients with acute coronary syndrome","volume":"38","author":"Okubo","year":"2023","journal-title":"Heart Vessels"},{"key":"10.1016\/j.arteri.2024.03.002_bib1165","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1016\/j.jcin.2022.05.050","article-title":"Impact of High Lipoprotein(a) Levels on Clinical Outcomes Following Peripheral Endovascular Therapy","volume":"15","author":"Tomoi","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.arteri.2024.03.002_bib1170","doi-asserted-by":"crossref","first-page":"2896","DOI":"10.1097\/MS9.0000000000000725","article-title":"Association of aortic dissection and lipoprotein (a): A meta-analysis","volume":"85","author":"Motawea","year":"2023","journal-title":"Ann Med Surg (Lond)"},{"key":"10.1016\/j.arteri.2024.03.002_bib1175","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.atherosclerosis.2022.04.016","article-title":"Lipoprotein (a) and diabetes mellitus","volume":"349","author":"Lamina","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1180","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1016\/j.jacc.2019.10.019","article-title":"Lipoprotein(a) Concentration and Risks of Cardiovascular Disease and Diabetes","volume":"74","author":"Gudbjartsson","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1185","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1373\/clinchem.2010.146779","article-title":"Lipoprotein(a) and risk of type 2 diabetes","volume":"56","author":"Mora","year":"2010","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib1190","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12933-017-0520-z","article-title":"Lipoprotein(a) and incident type-2 diabetes: Results from the prospective Bruneck study and a meta-analysis of published literature","volume":"16","author":"Paige","year":"2017","journal-title":"Cardiovasc Diabetol"},{"issue":"Suppl 2","key":"10.1016\/j.arteri.2024.03.002_bib1195","first-page":"S31","article-title":"Anti-PCSK9 antibodies in type 2 diabetes and secondary prevention of cardiovascular diseases [Article in Spanish]","volume":"28","author":"Lopez-Miranda","year":"2016","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.03.002_bib1200","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/j.numecd.2023.05.033","article-title":"Efficacy and safety of PCSK9 inhibitors in patients with diabetes: A systematic review and meta-analysis","volume":"33","author":"Chen","year":"2023","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1205","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1194\/jlr.R071233","article-title":"Lipoprotein (a) as a cause of cardiovascular disease: Insights from epidemiology, genetics, and biology","volume":"57","author":"Nordestgaard","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.03.002_bib1210","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.atherosclerosis.2018.06.863","article-title":"Lipoprotein(a) and apolipoprotein(a) isoform size: Associations with angiographic extent and severity of coronary artery disease, and carotid artery plaque","volume":"275","author":"Ooi","year":"2018","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1215","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1001\/jama.2009.801","article-title":"Genetically elevated lipoprotein(a) and increased risk of myocardial infarction","volume":"301","author":"Kamstrup","year":"2009","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2024.03.002_bib1220","doi-asserted-by":"crossref","first-page":"2160","DOI":"10.1016\/j.jacc.2009.10.080","article-title":"Apolipoprotein(a) isoforms and the risk of vascular disease: Systematic review of 40 studies involving 58,000 participants","volume":"55","author":"Erqou","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1225","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1161\/CIRCULATIONAHA.117.031356","article-title":"LPA Variants Are Associated With Residual Cardiovascular Risk in Patients Receiving Statins","volume":"138","author":"Wei","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.03.002_bib1230","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1161\/ATVBAHA.114.303462","article-title":"A common LPA null allele associates with lower lipoprotein(a) levels and coronary artery disease risk","volume":"34","author":"Kyriakou","year":"2014","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1235","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/j.jacc.2021.05.037","article-title":"Frequent LPA KIV-2 Variants Lower Lipoprotein(a) Concentrations and Protect Against Coronary Artery Disease","volume":"78","author":"Schachtl-Riess","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1240","first-page":"1","article-title":"Clinical Utility of Lipoprotein(a) and LPA Genetic Risk Score in Risk Prediction of Incident Atherosclerotic Cardiovascular Disease","volume":"6","author":"Trinder","year":"2020","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1245","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S2213-8587(17)30096-7","article-title":"Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease: A molecular and genetic association study","volume":"5","author":"Zewinger","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1250","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: A prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"key":"10.1016\/j.arteri.2024.03.002_bib1255","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1161\/CIRCULATIONAHA.116.026103","article-title":"A Replicated, Genome-Wide Significant Association of Aortic Stenosis With a Genetic Variant for Lipoprotein(a): Meta-Analysis of Published and Novel Data","volume":"135","author":"Cairns","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.03.002_bib1260","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamacardio.2017.4266","article-title":"Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Codes From Electronic Health Records","volume":"3","author":"Chen","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1265","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/cvr\/cvad062","article-title":"Lipoprotein(a) and calcific aortic valve disease initiation and progression: A systematic review and meta-analysis","volume":"119","author":"Pantelidis","year":"2023","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.arteri.2024.03.002_bib1270","doi-asserted-by":"crossref","first-page":"3532","DOI":"10.1161\/STROKEAHA.119.026872","article-title":"Causal Effect of Lp(a) [Lipoprotein(a)] Level on Ischemic Stroke and Alzheimer Disease: A Mendelian Randomization Study","volume":"50","author":"Pan","year":"2019","journal-title":"Stroke"},{"key":"10.1016\/j.arteri.2024.03.002_bib1275","doi-asserted-by":"crossref","first-page":"2761","DOI":"10.1016\/j.jacc.2016.10.033","article-title":"Phenotypic Characterization of Genetically Lowered Human Lipoprotein(a) Levels","volume":"68","author":"Emdin","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1280","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1038\/s41591-019-0492-5","article-title":"Genome-wide association study of peripheral artery disease in the Million Veteran Program","volume":"25","author":"Klarin","year":"2019","journal-title":"Nat Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1285","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1016\/j.amjcard.2010.01.370","article-title":"Lipoprotein(a), inflammation, and peripheral arterial disease in a community-based sample of older men and women (the InCHIANTI study)","volume":"105","author":"Volpato","year":"2010","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1290","doi-asserted-by":"crossref","first-page":"1866","DOI":"10.1373\/clinchem.2017.277103","article-title":"Type 2, Not Low Lipoprotein(a), as a Cause of Diabetes: A Novel Genetic Approach Using SNPs Associated Selectively with Lipoprotein(a) Concentrations or with Kringle IV Type 2 Repeats","volume":"63","author":"Tolbus","year":"2017","journal-title":"Clin Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib1295","doi-asserted-by":"crossref","first-page":"e0149427","DOI":"10.1371\/journal.pone.0149427","article-title":"Apolipoprotein(a) Kringle-IV Type 2 Copy Number Variation Is Associated with Venous Thromboembolism","volume":"11","author":"Sticchi","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.arteri.2024.03.002_bib1300","first-page":"91","article-title":"Consensus document for lipid profile determination and reporting in Spanish clinical laboratories. What parameters should be included in a basic lipid profile?","volume":"35","author":"Arrobas Velilla","year":"2023","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.03.002_bib1305","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.atherosclerosis.2019.10.011","article-title":"HEART UK consensus statement on Lipoprotein(a): A call to action","volume":"291","author":"Cegla","year":"2019","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1310","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.03.002_bib1315","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1093\/eurheartj\/ehz455","article-title":"2019 ESC\/EAS Guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2020","journal-title":"Eur Heart J."},{"key":"10.1016\/j.arteri.2024.03.002_bib1320","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.cjca.2021.03.016","article-title":"2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults","volume":"37","author":"Pearson","year":"2021","journal-title":"Can J Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1325","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1330","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1093\/eurjpc\/zwab180","article-title":"Measuring lipoprotein(a): Do it without ifs and buts","volume":"29","author":"Kronenberg","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1335","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jacc.2021.11.055","article-title":"Repeat Measures of Lipoprotein(a) Molar Concentration and Cardiovascular Risk","volume":"79","author":"Trinder","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1340","first-page":"128","article-title":"Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Sociey of Arteriosclerosis (SEA)","volume":"31","author":"Ascaso","year":"2019","journal-title":"Clin Investig Arterioscler"},{"key":"10.1016\/j.arteri.2024.03.002_bib1345","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s11789-019-00093-5","article-title":"Prediction of cardiovascular risk by Lp(a) concentrations or genetic variants within the LPA gene region","volume":"14","author":"Kronenberg","year":"2019","journal-title":"Clin Res Cardiol Suppl"},{"key":"10.1016\/j.arteri.2024.03.002_bib1350","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.atherosclerosis.2022.04.020","article-title":"Existing and emerging strategies to lower Lipoprotein(a)","volume":"349","author":"Schwartz","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1355","author":"Ference","year":"2021","journal-title":"Lp(a) clinical guidance"},{"key":"10.1016\/j.arteri.2024.03.002_bib1360","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jacc.2014.03.061","article-title":"Discrimination and net reclassification of cardiovascular risk with lipoprotein(a): Prospective 15-year outcomes in the Bruneck Study","volume":"64","author":"Willeit","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1365","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1016\/j.jacc.2017.01.017","article-title":"Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms","volume":"69","author":"Verbeek","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1370","first-page":"e563","article-title":"2019 ACC\/AHA Guideline on the Primary Prevention of Cardiovascular Disease: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"140","author":"Arnett","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.03.002_bib1375","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1186\/s12944-019-1092-6","article-title":"Prognostic value of lipoprotein (a) level in patients with coronary artery disease: A meta-analysis","volume":"18","author":"Wang","year":"2019","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1380","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.jacc.2013.06.051","article-title":"Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: The AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL\/High Triglyceride and Impact on Global Health Outcomes)","volume":"62","author":"Albers","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1385","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(18)31652-0","article-title":"Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: Individual patient-data meta-analysis of statin outcome trials","volume":"392","author":"Willeit","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2024.03.002_bib1390","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.jacc.2018.04.060","article-title":"Lipoprotein(a) and Cardiovascular Risk Prediction Among Women","volume":"72","author":"Cook","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1395","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jacc.2014.01.088","article-title":"Nonpharmacological lipoprotein apheresis reduces arterial inflammation in familial hypercholesterolemia","volume":"64","author":"van Wijk","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1400","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1177\/2047487320938271","article-title":"Use of lipoprotein(a) for refining cardiovascular risk prediction in a low-risk population: The CoLaus\/PsyCoLaus study","volume":"28","author":"Delabays","year":"2021","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1405","unstructured":"NCT02791802. Effect of Lipoprotein(a) Elimination by Lipoprotein Apheresis on Cardiovascular Outcomes - Full Text View 2023."},{"key":"10.1016\/j.arteri.2024.03.002_bib1410","doi-asserted-by":"crossref","first-page":"979","DOI":"10.2174\/0929867324666170124144427","article-title":"Lipoprotein (a) Management: Lifestyle and Hormones","volume":"24","author":"Garcia-Rios","year":"2017","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.arteri.2024.03.002_bib1415","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40256-020-00437-7","article-title":"Emerging Pharmacotherapy to Reduce Elevated Lipoprotein(a) Plasma Levels","volume":"21","author":"Eraikhuemen","year":"2021","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.arteri.2024.03.002_bib1420","doi-asserted-by":"crossref","first-page":"2042","DOI":"10.1161\/ATVBAHA.115.305835","article-title":"Effects of Extended-Release Nicotinic Acid on Apolipoprotein (a) Kinetics in Hypertriglyceridemic Patients","volume":"35","author":"Croyal","year":"2015","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1425","doi-asserted-by":"crossref","first-page":"e001696","DOI":"10.1161\/CIRCGEN.117.001696","article-title":"Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study","volume":"11","author":"Parish","year":"2018","journal-title":"Circ Genom Precis Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1430","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/eurjpc\/zwab171","article-title":"Statin therapy and lipoprotein(a) levels: A systematic review and meta-analysis","volume":"29","author":"de Boer","year":"2022","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1435","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/S0140-6736(12)61731-0","article-title":"Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: A single-arm, open-label, phase 3 study","volume":"381","author":"Cuchel","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2024.03.002_bib1440","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/ncpcardio1250","article-title":"Inhibition of microsomal triglyceride transfer protein alone or with ezetimibe in patients with moderate hypercholesterolemia","volume":"5","author":"Samaha","year":"2008","journal-title":"Nat Clin Pract Cardiovasc Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1445","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1007\/s40265-018-0870-1","article-title":"Effect of Ezetimibe Monotherapy on Plasma Lipoprotein(a) Concentrations in Patients with Primary Hypercholesterolemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"78","author":"Awad","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.arteri.2024.03.002_bib1450","doi-asserted-by":"crossref","first-page":"17887","DOI":"10.1038\/s41598-018-36204-7","article-title":"Impact of ezetimibe on plasma lipoprotein(a) concentrations as monotherapy or in combination with statins: A systematic review and meta-analysis of randomized controlled trials","volume":"8","author":"Sahebkar","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.arteri.2024.03.002_bib1455","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jacl.2015.03.003","article-title":"Use of ETC-1002 to treat hypercholesterolemia in patients with statin intolerance","volume":"9","author":"Thompson","year":"2015","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1460","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jacl.2023.02.002","article-title":"Effects of bempedoic acid on CRP, IL-6, fibrinogen and lipoprotein(a) in patients with residual inflammatory risk: A secondary analysis of the CLEAR harmony trial","volume":"17","author":"Ridker","year":"2023","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1465","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.jacl.2021.05.002","article-title":"Lipid lowering with bempedoic acid added to a proprotein convertase subtilisin\/kexin type 9 inhibitor therapy: A randomized, controlled trial","volume":"15","author":"Rubino","year":"2021","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1470","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1001\/jamacardio.2022.0987","article-title":"Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review","volume":"7","author":"Duarte Lau","year":"2022","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1475","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/FJC.0000000000000963","article-title":"Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin\/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis","volume":"77","author":"Farmakis","year":"2021","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1480","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.jacc.2019.10.057","article-title":"Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome","volume":"75","author":"Bittner","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1485","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1161\/CIRCULATIONAHA.118.037184","article-title":"Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk","volume":"139","author":"O\u2019Donoghue","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.arteri.2024.03.002_bib1490","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1495","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1038\/s41591-022-01936-7","article-title":"Lipid lowering effects of the CETP inhibitor obicetrapib in combination with high-intensity statins: A randomized phase 2 trial","volume":"28","author":"Nicholls","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1500","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1194\/jlr.R056549","article-title":"Lipoprotein apheresis to treat elevated lipoprotein (a)","volume":"57","author":"Waldmann","year":"2016","journal-title":"J Lipid Res"},{"key":"10.1016\/j.arteri.2024.03.002_bib1505","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1093\/eurheartj\/ehx178","article-title":"Apheresis as novel treatment for refractory angina with raised lipoprotein(a): A randomized controlled cross-over trial","volume":"38","author":"Khan","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.03.002_bib1510","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1016\/j.jacc.2021.01.051","article-title":"Emerging RNA Therapeutics to Lower Blood Levels of Lp(a): JACC Focus Seminar 2\/4","volume":"77","author":"Tsimikas","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1515","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): Two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.arteri.2024.03.002_bib1520","unstructured":"NCT04023552. Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Major Cardiovascular Events in Patients With CVD 2023."},{"key":"10.1016\/j.arteri.2024.03.002_bib1525","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41591-021-01634-w","article-title":"Preclinical development and phase 1 trial of a novel siRNA targeting lipoprotein(a)","volume":"28","author":"Koren","year":"2022","journal-title":"Nat Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1530","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1056\/NEJMoa2211023","article-title":"Small Interfering RNA to Reduce Lipoprotein(a) in Cardiovascular Disease","volume":"387","author":"O\u2019Donoghue","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1535","unstructured":"NCT05581303. OLp(a)siran Trials of Cardiovascular Events and Lipoprotein(a) Reduction (OCEAN(a)) - Outcomes Trial 2023."},{"key":"10.1016\/j.arteri.2024.03.002_bib1540","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2022.5050","article-title":"Single Ascending Dose Study of a Short Interfering RNA Targeting Lipoprotein(a) Production in Individuals With Elevated Plasma Lipoprotein(a) Levels","volume":"327","author":"Nissen","year":"2022","journal-title":"JAMA"},{"key":"10.1016\/j.arteri.2024.03.002_bib1545","unstructured":"NCT04606602. Study to Investigate Safety, Tolerability, PK and PD Response of SLN360 in Subjects With Elevated Lipoprotein(a). 2023."},{"key":"10.1016\/j.arteri.2024.03.002_bib1550","unstructured":"NCT05565742. A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of LY3819469 in Adults With Elevated Lipoprotein(a) 2023."},{"key":"10.1016\/j.arteri.2024.03.002_bib1555","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/j.jacc.2023.02.033","article-title":"Clinical Trial Design for Lipoprotein(a)-Lowering Therapies: JACC Focus Seminar 2\/3","volume":"81","author":"Malick","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1560","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1001\/jamacardio.2018.1470","article-title":"Association of LPA Variants With Risk of Coronary Disease and the Implications for Lipoprotein(a)-Lowering Therapies: A Mendelian Randomization Analysis","volume":"3","author":"Burgess","year":"2018","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1565","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1093\/eurheartj\/ehq386","article-title":"Lipoprotein(a) as a cardiovascular risk factor: Current status","volume":"31","author":"Nordestgaard","year":"2010","journal-title":"Eur Heart J"},{"key":"10.1016\/j.arteri.2024.03.002_bib1570","article-title":"SEA 2024 Standards for Global Control of Cardiovascular Risk [Article in English, Spanish]","author":"Mostaza","year":"2024","journal-title":"Clin Investig Arterioscler."},{"key":"10.1016\/j.arteri.2024.03.002_bib1575","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.atherosclerosis.2022.04.015","article-title":"Lipoprotein(a) and cardiovascular and valvular diseases: A genetic epidemiological perspective","volume":"349","author":"Arsenault","year":"2022","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1580","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/1475-2840-11-81","article-title":"High levels of lipoprotein(a) are associated with a lower prevalence of diabetes with advancing age: Results of a cross-sectional epidemiological survey in Gran Canaria, Spain","volume":"11","author":"Boronat","year":"2012","journal-title":"Cardiovasc Diabetol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1585","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.recesp.2022.03.006","article-title":"Lipoprote\u00edna (a) en una selecci\u00f3n de hospitales de Andaluc\u00eda y Extremadura. \u00bfInfradiagnosticada e infrautilizada?","volume":"75","author":"Arrobas Velilla","year":"2022","journal-title":"Rev Esp Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1590","first-page":"402","article-title":"Caracter\u00edsticas cl\u00ednicas asociadas a niveles elevados de lipoprote\u00edna(a)\u00a0en pacientes atendidos por riesgo vascular","volume":"4","author":"Rubio-Serrano","year":"2023","journal-title":"Adv Lab Med"},{"key":"10.1016\/j.arteri.2024.03.002_bib1595","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2018.12.037","article-title":"Value of Measuring Lipoprotein(a) During Cascade Testing for Familial Hypercholesterolemia","volume":"73","author":"Ellis","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1600","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.atherosclerosis.2016.11.010","article-title":"Ideal cardiovascular health influences cardiovascular disease risk associated with high lipoprotein(a) levels and genotype: The EPIC-Norfolk prospective population study","volume":"256","author":"Perrot","year":"2017","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.arteri.2024.03.002_bib1605","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/j.jacc.2021.04.102","article-title":"Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol","volume":"78","author":"Schwartz","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.arteri.2024.03.002_bib1610","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1016\/j.jacc.2022.07.027","article-title":"Aspirin for Primary Prevention of Cardiovascular Events in Relation to Lipoprotein(a) Genotypes","volume":"80","author":"Lacaze","year":"2022","journal-title":"J Am Coll Cardiol"}],"container-title":["Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis"],"original-title":[],"language":"es","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916824000238?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0214916824000238?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,5]],"date-time":"2024-07-05T18:32:01Z","timestamp":1720204321000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0214916824000238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7]]},"references-count":161,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,7]]}},"alternative-id":["S0214916824000238"],"URL":"https:\/\/doi.org\/10.1016\/j.arteri.2024.03.002","relation":{"withdrawal":[{"id-type":"doi","id":"10.1016\/j.artere.2024.04.001","asserted-by":"object"}]},"ISSN":["0214-9168"],"issn-type":[{"value":"0214-9168","type":"print"}],"subject":[],"published":{"date-parts":[[2024,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Consenso sobre lipoprote\u00edna (a) de la Sociedad Espa\u00f1ola de Arteriosclerosis. Revisi\u00f3n bibliogr\u00e1fica y recomendaciones para la pr\u00e1ctica cl\u00ednica","name":"articletitle","label":"Article Title"},{"value":"Cl\u00ednica e Investigaci\u00f3n en Arteriosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.arteri.2024.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Sociedad Espa\u00f1ola de Arteriosclerosis. Published by Elsevier Espa\u00f1a, S.L.U. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}